Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer

Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer

Abstract Background This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non‐small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD‐1/PD‐L1 therapy) combined with chemotherapy or anti‐ang...

Full description

Bibliographic Details
Main Authors: Li‐Yue Sun, Wen‐Jian Cen, Wen‐Ting Tang, Ya‐Kang Long, Xin‐Hua Yang, Xiao‐Meng Ji, Jiao‐Jiao Yang, Ren‐Jing Zhang, Fang Wang, Jian‐Yong Shao, Zi‐Ming Du
Format: Article
Language:English
Published: Wiley 2021-10-01
Series:Cancer Medicine
Subjects:
combination therapy
immune checkpoint inhibitor
non‐small cell lung cancer
smoking
tumor mutational burden
Online Access:https://doi.org/10.1002/cam4.4197

Internet

https://doi.org/10.1002/cam4.4197

Similar Items